Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sanofi Japan sees growth for new products but generics bite

This article was originally published in Scrip

Executive Summary

Sanofi is expecting growth of around 8% for its patent-protected portfolio of pharmaceuticals in Japan this year, although there will be negative impacts on its broader business in the sector from the general reimbursement price cut in April and generic erosion for older products.The company declined to provide an overall forecast but said that its Japanese drug business declined by around 4% at reimbursement prices in calendar 2013 to JPY317.7bn ($3.0bn), with top product Plavix (clopidogrel) growing by 14% to JPY116.8bn, ahead of the 1.6% increase in the total antiplatelet market.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

SC024939

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel